Why the market is shifting now
Healthcare AI now sits inside workflows that affect clinical decisions, utilization management, patient access, and provider productivity. That expansion changes the risk profile. At Brillio, our HLS teams help clients industrialize AI responsibly, embedding governance, observability, security, explainability, and compliance directly into products, platforms, and operating models. Here’s why we believe the market is shifting:
- AI is moving closer to patient-impacting workflows. When it influences diagnosis, triage, treatment, or coverage, tolerance for opacity drops sharply.
- GenAI adoption is accelerating. Clinical copilots and patient chatbots introduce hallucination, prompt manipulation, protected health information (PHI) leakage, and inconsistent answer quality.
- Agentic AI is creating new control challenges. As agents trigger actions and retrieve data, enterprises must define limits, intervention points, and audit trails.
- Regulators are applying existing laws to new AI behaviors. Device oversight, civil rights enforcement, and consumer protection now govern AI-enabled decisions.
- Trust is becoming a commercial requirement. Buyers, clinicians, and patients expect evidence of safety, fairness, and accountability before adoption scales.
AI governance should be treated as an enterprise capability, not a compliance checkpoint. Enterprises that embed governance into AI delivery will move faster because they can approve, monitor, and scale trusted use cases with less friction.
Regulation is arriving from every direction. Unlike the EU, the US has no single comprehensive federal AI law currently. Instead, oversight is emerging at once from the FDA, HHS, CMS, the FTC, and a fast-growing patchwork of state rules. The implication is clear: healthcare AI governance must now cover the full lifecycle, from intake and risk classification through validation, monitoring, incident response, and retirement.
